COMMUNIQUÉS West-GlobeNewswire
-
Nyxoah Provides an Update on Expanded Middle East Presence
23/09/2025 -
Nyxoah Présente les Dernières Avancées Concernant son Expansion au Moyen-Orient
23/09/2025 -
Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health
23/09/2025 -
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
23/09/2025 -
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
23/09/2025 -
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
23/09/2025 -
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
23/09/2025 -
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
23/09/2025 -
Ron Schaefer Named President and CEO of Emerald Communities, Emerald Heights, and Heron’s Key
23/09/2025 -
PhenQ Australia Over the Counter | Fast Acting Fat Burner and Appetite Suppressant Australian Launch OTC by PhenQ
23/09/2025 -
UPDATE - Shotsy Names Eric Perakslis as Chief Science Officer to Advance Safe, Science-Backed GLP-1 Support
23/09/2025 -
Dunham House Opens Applications for Residents
23/09/2025 -
Supplements For Testosterone Booster 2025: TestoPrime” Natural Testosterone Booster Supplement For Men 40 or 50 launch in USA.
23/09/2025 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2025
23/09/2025 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 38 - 2025
23/09/2025 -
Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist to OTCQB
23/09/2025 -
Confluent Health Appoints Jim Greenwood as New Board Chair
23/09/2025 -
PathAI Launches Industry-Backed AIM-HI UC Model on GCP-Compliant Platform to Standardize Histological Assessment in Ulcerative Colitis Trials
23/09/2025 -
LogicMark Launches Predictive Activity Metrics in Freedom Alert Max Device
23/09/2025
Pages